Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion

Laborértékek

• Two or more clinical characteristics at baseline (age≥80 years, body weight ≤60 kg, serum creatinine ≥1.5 mg/dL) requiring apixaban dosage adjustment;
  • Mechanical heart valves or valvular disease requiring surgery or interventional procedure;
  • Mandatory indication for dual antiplatelet therapy (e.g. recent stent) or single anti-platelet treatment (SAPT) (e.g. high coronary risk);
  • Any contra-indication or known allergy to aspirin or clopidogrel or apixaban;
  • Any mandatory indication for anticoagulation for a reason other than AF (e.g. Pulmonary embolism);
  • Ongoing major bleeding or complicated or recent (<72hours) major surgery;
  • Recent myocardial infarction (<6 weeks);
  • Recent TE event (<6 weeks)
  • Recent Intracranial bleeding (< 6 months);
  • Prasugrel or ticagrelor concomitant use
  • Participating in an investigational drug or another device trial within the previous 30 days;
  • High likelihood of being unavailable for follow-up or psycho-social condition making study participation impractical;
  • Pregnancy or within 48 hours post-partum or breast feeding women;
  • Patient under legal protection.

• • Men and women ≥18 years of age;
  • Patients who underwent a clinically successful LAA closure procedure with a Watchman device (device implanted without procedural or bleeding complication) within a day or are scheduled to undergo the LAAO procedure
  • Paroxysmal, persistent, or permanent AF patients irrespective of prior antithrombotic treatment are eligible for randomization,
  • Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.